Cargando…
Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Internal Medicine
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338249/ https://www.ncbi.nlm.nih.gov/pubmed/37424499 http://dx.doi.org/10.3904/kjim.2023.248 |
| _version_ | 1785071590025723904 |
|---|---|
| author | Shin, Hyun Phil |
| author_facet | Shin, Hyun Phil |
| author_sort | Shin, Hyun Phil |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10338249 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The Korean Association of Internal Medicine |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103382492023-07-14 Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection Shin, Hyun Phil Korean J Intern Med Editorial The Korean Association of Internal Medicine 2023-07 2023-06-30 /pmc/articles/PMC10338249/ /pubmed/37424499 http://dx.doi.org/10.3904/kjim.2023.248 Text en Copyright © 2023 The Korean Association of Internal Medicine https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorial Shin, Hyun Phil Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection |
| title | Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection |
| title_full | Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection |
| title_fullStr | Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection |
| title_full_unstemmed | Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection |
| title_short | Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection |
| title_sort | sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis c infection |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338249/ https://www.ncbi.nlm.nih.gov/pubmed/37424499 http://dx.doi.org/10.3904/kjim.2023.248 |
| work_keys_str_mv | AT shinhyunphil sofosbuvirvelpatasvirandsofosbuvirvelpatasvirvoxilaprevirnoveltreatmentoptionsfornaiveandpreviouslytreatedhepatitiscinfection |